Plain-English translation of NCT06271252 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial testing a new treatment called , which is a type of cell therapy designed to fight multiple myeloma — a blood cancer that has come back or stopped responding to previous treatments. The medication works by using your own immune cells that are specially engineered in the laboratory to target and destroy myeloma cells. Researchers want to learn whether this treatment is safe, how it works in the body, and whether it helps control the disease.
Multiple myeloma is a serious blood cancer, and patients often develop resistance to standard treatments over time. This trial exists to explore whether this new cell therapy can offer hope to people whose cancer has returned or no longer responds to available options.
You likely qualify if…
You likely don't qualify if…
You would receive a single infusion of the medication through an IV, likely over a few hours at a hospital or clinic. The trial has different stages — starting with careful safety monitoring of smaller groups, then expanding to larger groups as safety is established. You would have multiple follow-up visits to check your blood counts, measure disease response, and watch for any side effects. The study will track how long the medication stays in your body and how well it works against your myeloma over time.
AI-generated summary from trial data · Jul 1, 2026 · Not medical advice
United States